Fig. 7
IGF2BP1-induced murine neuroblastoma comprises syntenic chromosomal aberrations and gene expression profiles observed in human high-risk disease. a-c Frequency (%) of DNA copy number gains (red) and losses (blue) for murine chromosome 1 to 19 in R26IGF2BP1/MYCN (a) or R26IGF2BP1 (b) tumors compared to wildtype adrenal glands and lift over of R26IGF2BP1 regions to the human genome (c, Chr 1–22). Overlay of human neuroblastoma sWGS is depicted in transparent colors (c). d Selected hallmark gene sets in R26IGF2BP1 (TI), R26IGF2BP1/MYCN (TIM) or R26MYCN (AGM) mice based on GSEA. e RNA-seq analysis of indicated mRNAs presented as log2 fold change (log2FC) compared to wildtype adrenal glands. f Correlation of NES values of C2 (left) and M2 (right) gene sets between TI and TIM. Non-significant gene sets are depicted in grey. g Log2FC of miRNAs from the miR-17–92 cluster and let-7 family between R26IGF2BP1 or R26IGF2BP1/MYCN tumors and normal adrenal gland tissue. SCNEC/LCNEC—genetic mouse model high-grade small/large-cell neuroendocrine lung carcinoma